My PCR Releases New Resource on Treatment Free Remission (TFR)
My PCR has released a new FAQ about Treatment Free Remission (TFR) – a potential treatment goal for some patients living with chronic myeloid leukemia (CML).
The Max Foundation Renews and Expands Agreement with Incyte
The Max Foundation is proud to announce it has signed a renewed collaboration agreement with Incyte – a dedicated pharmaceutical partner and member of our humanitarian pact.
Since February 2017, Incyte has partnered with The Max Foundation to assist patients with cancer in Central Asia and Eastern Europe who are in need and unable to access treatment. The renewal by Incyte will allow The Max Foundation, through our drug donation program Max Access Solutions, to expand the number of patients who may be eligible to receive treatment with Iclusig (ponatinib) from 35 to up to 50 at no cost for as long as needed.
“As we work to expand treatment access for patients in low-income countries, we are grateful to have committed partners like Incyte,” said Pat Garcia-Gonzalez, CEO and co-founder of The Max Foundation. “We’re so excited to not only continue our collaboration, but also to expand its size and bring effective medicine to more patients in need.”
“At Incyte we are fully aligned with the mission of The Max Foundation, focused on increasing patient access to care, support, and treatment,” added Jonathan Dickinson, General Manager of Incyte in Europe. “We are proud to be part of a program dedicated to making cancer treatments available to appropriate patients in Central Asia and Eastern Europe. We are happy and privileged to partner with and support to The Max Foundation’s efforts and look forward to another year of making a difference for patients with cancer.”
We at The Max Foundation express our thanks to Incyte for their continued collaboration, and will keep an ear out for the Incyte Bell (pictured below, and rung once each week for each new patient treated).
The Max Foundation is a leading global health nonprofit organization dedicated to accelerating health equity. For 28 years, Max has pioneered practical, scalable, high-quality solutions to bring life-extending treatments and patient-centered health care to more than 100,000 people living with cancer and critical illness in low- and middle-income countries. Max believes in a world where all people can access high-impact medicines, where geography is not destiny, and where everyone can strive for health with dignity and with hope.
Related Articles
The Max Foundation, BeiGene, and the BeiGene Foundation Announce Collaboration to Advance Health Equity by Providing Access to BRUKINSA® for the Treatment of Chronic Lymphocytic Leukemia in Low- and Middle-Income Countries
SEATTLE, Washington – May 17, 2023 – The Max Foundation (Max), a global nonprofit organization dedicated to accelerating health equity by delivering medication, technology, and supportive services to patients worldwide, BeiGene, a global biotechnology company, and the BeiGene Foundation, a nonprofit charitable foundation, today announced a collaboration to provide access to BRUKINSA (zanubrutinib) for the….
UICC announces a new global coalition to increase access to and the use of essential cancer medicines in low- and lower middle-income countries
The Union for International Cancer Control (UICC) and multiple partners* are establishing the Access to Oncology Medicines (ATOM) Coalition, a new global partnership to increase access to quality-assured essential cancer medicines in low- and lower middle-income countries (LLMICs) and to help countries develop the capacity for their proper use. It is estimated that less than….